Pharmeuropa Chapter 2.1.7. Balances for Analytical Purposes published for Comments

Recommendation
Wednesday, 1 October 2025 13.00 - 17.00 h
In the Pharmeuropa issue 37.1, a proposal for a revised chapter 2.1.7. Balances for analytical purposes has been published for public consultation.
The revised chapter, like the current version, focuses exclusively on balances used for analytical purposes, excluding those used in manufacturing or other applications.
The draft introduces definitions for two types of balances, multi-interval and multiple range balances, distinguished by how their capacity is segmented. The new definitions are as follows:
- "Multi-interval balance: balance having one weighing range divided into partial ranges, each with different scale intervals d; when tared after a load has been applied, the balance returns to the finest range, i.e. the weighing range with the smallest scale interval d."
- "Multiple range balance: balance having more than one weighing range, each with different scale intervals d; when tared after a load has been applied, the balance remains in the weighing range that refers to the load value applied."
Additionally, the revision includes updates to technical terminology related to equipment performance. Among other clarifications, the following sentence has been added:
- "Calibrations and performance checks must be carried out under conditions that accurately represent the routine operating conditions of the balance."
The section on minimum weight has also been expanded to provide further guidance.
The complete draft, along with detailed information on the revisions, is available on the Pharmeuropa website (registration required). Comments can be submitted until 31 March 2025.
Related GMP News
02.07.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls
25.06.2025FDA Warning Letter: "Memory-Based Manufacturing" and Lack of Analytical Testing
11.06.2025USP informs about Monographs affected by the Revision of NMR Chapters <761> and <1761>
28.05.2025FDA Warning Letter for Chinese Manufacturer: Inadequate Testing and Stability Program Deficiencies